Lifecore Biomedical, Inc. DE
LFCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001005286
No open-market purchases or sales by Lifecore Biomedical, Inc. DE insiders were filed in the last 90 days; 98 institutions reported holding it in 13F filings for Q2 2026, worth $133.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 98
- 13F valueReported value at the end of Q2 2026
- $133.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LFCR, Q2 2026
No superinvestor reported holding LFCR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lifecore Biomedical, Inc. DE insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2025 (view filing)8:06 PM ET | May 23-28 | 5 days | 22NW Fund, LP and 4 others10% Owner | SSale | −1.39M | $6.59 | −$9.13M | −84.0%264.2K after | 3 lots |
| May 16, 2025 (view filing)11:28 AM ET | May 13 | 3 daysLate | 22NW Fund, LP and 4 others10% Owner | SSale | −12.3K | $7.00 | −$86.4K | −0.7%1.65M after | |
| May 12, 2025 (view filing)6:58 PM ET | May 8-12 | 4 days | 22NW Fund, LP and 4 others10% Owner | SSale | −51.5K | $7.03 | −$362.0K | −3.0%1.66M after | 3 lots |
| May 7, 2025 (view filing)9:09 PM ET | May 5-7 | 2 days | 22NW Fund, LP and 4 others10% Owner | SSale | −41.1K | $7.05 | −$289.9K | −2.3%1.71M after | 3 lots |
| Jan 8, 2025 (view filing) | Jan 8 | Same day | Josephs PaulChief Executive Officer | PPurchase | +17.0K | $5.74 | +$97.6K | +3.1%559.7K after | |
| Oct 7, 2024 (view filing)8:45 PM ET | Oct 3 | 4 days | Wynnefield Partners Small Cap Value LP and 7 others10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +122.9K | $4.10 | +$504.0K | +6.2%2.10M after | |
| Oct 7, 2024 (view filing)8:45 PM ET | Oct 3 | 4 days | Wynnefield Partners Small Cap Value LP and 7 others10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +169.8K | $4.10 | +$696.0K | +7.0%2.61M after | |
| Oct 7, 2024 (view filing)4:33 PM ET | Oct 3 | 4 days | Kiper Christopher S and 6 othersDirector, 10% Owner | PPurchase | +1.46M | $4.10 | +$6.00M | New position319.3K after | 2 lots |
| Jan 18, 2023 (view filing)5:23 PM ET | Nov 25, 2022 | 54 daysLate | Wynnefield Partners Small Cap Value LP and 7 others10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +345.3K | $7.97 | +$2.75M | +21.2%1.97M after | |
| Jan 18, 2023 (view filing)5:23 PM ET | Nov 25, 2022 | 54 daysLate | Wynnefield Partners Small Cap Value LP and 7 others10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +282.5K | $7.97 | +$2.25M | +13.1%2.44M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lifecore Biomedical, Inc. DE at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wynnefield Capital Inc | 4,703,216 | $24.7M | 16.98% | 00.0% | Unchanged |
| Legion Partners Asset Management, LLC | 4,461,823 | $23.4M | 57.75% | 00.0% | Unchanged |
| Greenhaven Road Investment Management, L.P. | 3,190,769 | $16.8M | 10.88% | −346,804−9.8% | Reduced |
| 325 Capital LLC | 2,895,881 | $15.2M | 3.62% | +733,415+33.9% | Added |
| BlackRock, Inc. | 2,013,093 | $10.6M | 0.00% | +135,788+7.2% | Added |
| Vanguard Capital Management LLC | 1,288,621 | $6.77M | 0.00% | −1,515−0.1% | Reduced |
| Geode Capital Management, LLC | 855,500 | $4.49M | 0.00% | +40,393+5.0% | Added |
| Morgan Stanley | 769,360 | $4.04M | 0.00% | +4,626+0.6% | Added |
| State Street Corp | 668,031 | $3.51M | 0.00% | +26,025+4.1% | Added |
| Quinn Opportunity Partners LLC | 453,495 | $2.38M | 0.11% | 00.0% | Unchanged |